Dynavax May Offer An Opportunity In The Hepatitis B Space
November 13, 2014 at 17:35 PM EST
Dynavax's Hepatitis B vaccine Hepislav has the opportunity to bounce back; a first review is positive but there is a ways to go.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.